2. Search Result
Search Result
Results for "

small intestinal

" in MedChemExpress (MCE) Product Catalog:

68

Inhibitors & Agonists

1

Fluorescent Dyes

1

Biochemical Assay Reagents

10

Peptides

1

MCE Kits

15

Natural
Products

11

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-16569
    Colchicine
    60+ Cited Publications

    		 Environmental Pollutants Apoptosis Autophagy Microtubule/Tubulin NOD-like Receptor (NLR) Cancer
    Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
    Colchicine
  • HY-114299
    Salcaprozate sodium
    4 Publications Verification

    SNAC

    		 Biochemical Assay Reagents Others
    Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .
    Salcaprozate sodium
  • HY-B0113
    Omeprazole
    5+ Cited Publications

    H 16868

    		 Na+/K+ ATPase Proton Pump Bacterial Cytochrome P450 Apoptosis Autophagy Atg8/LC3 TNF Receptor Interleukin Related Infection Neurological Disease Inflammation/Immunology Cancer
    Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole
  • HY-B1190
    Cefadroxil
    5 Publications Verification

    BL-S 578

    		 Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil
  • HY-D1736
    BODIPY FL-C16

    		Fluorescent Dye Others
    BODIPY FL-C16 is a BODIPY-labeled analog of Palmitic acid (HY-N0830), which serves as a fluorescent lipid tracer. BODIPY FL-C16 also acts as a ligand for liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) , with Kd values of 270 nM and 330 nM, respectively. BODIPY FL-C16 is rapidly taken up by cells, and after metabolic conversion to phospholipids, it is incorporated into the membrane structures of intracellular organelles and extracellular vesicles .
    BODIPY FL-C16
  • HY-W008491
    TK-112690

    		Phosphorylase Inflammation/Immunology Cancer
    TK-112690 is a UPP1 inhibitor. TK-112690 inhibits murine small intestinal uridine phosphorylase (UPase) with an IC50 of 12.5 μM and human small intestinal UPase with an IC50 of 20.0 μM in vitro. TK-112690 increases plasma uridine concentration in mice. TK-112690 can be used for the study of cancer and pulmonary fibrosis .
    TK-112690
  • HY-B0113A
    Omeprazole sodium
    5+ Cited Publications

    H 16868 sodium

    		 Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Inflammation/Immunology
    Omeprazole (H 16868) sodium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole sodium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole sodium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole sodium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole sodium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole sodium aslo has neuroprotective and antibacterial effects .
    Omeprazole sodium
  • HY-112484
    RS-246204
    2 Publications Verification

    		 Organoid Cancer
    RS-246204 is a R-spondin-1 substitute compound that is able initiate small intestinal organoids without the use of the R-spondin-1 protein.
    RS-246204
  • HY-P2221
    Glepaglutide
    1 Publications Verification

    ZP1848

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848), a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide reduces faecal output and increases intestinal absorption. Glepaglutide alleviates small intestinal inflammation. Glepaglutide can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide
  • HY-111237
    Butyrolactone I

    Olomoucin

    		 CDK NF-κB PERK Bcl-2 Family Reactive Oxygen Species (ROS) Apoptosis Metabolic Disease Inflammation/Immunology Cancer
    Butyrolactone I is an orally active and ATP-competitive inhibitor of CDK1. Butyrolactone I inhibits NF-κB, cdc2 kinase, Bax, ROS production, modulates the PERK/CHOP. Butyrolactone I mitigates heat-stress-induced Apoptosis. Butyrolactone I shows anti-inflammatory and intestinal protective activity. Butyrolactone I has antitumor effects against non-small cell lung, small cell lung, prostate cancer and leukemia. Butyrolactone I can be used in NASH research .
    Butyrolactone I
  • HY-P1108A
    Astressin 2B TFA
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B TFA is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B TFA blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B TFA reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B TFA also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B TFA mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B TFA is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B TFA
  • HY-P5005
    VIPhyb

    		CMV PD-1/PD-L1 Infection Inflammation/Immunology Cancer
    VIPhyb is a vasoactive intestinal polypeptide (VIP) receptor antagonist. VIPhyb can inhibit VIP signaling, increase T-cell immunity and downregulate PD1. VIPhyb can inhibit cancer cell proliferation. VIPhyb can reduce inflammatory cytokine expression. VIPhyb can enhance viral clearance. VIPhyb can be used for the researches of cancer, infection and inflammation and immunology, such as non-small cell lung cancer (NSCLC), cytomegalovirus infection and colitis .
    VIPhyb
  • HY-106449
    Recoflavone

    DA-6034 free acid

    		 NF-κB COX Apoptosis ERK Calcium Channel Inflammation/Immunology Cancer
    Recoflavone (DA-6034 (free acid)), a synthetic derivative of the flavonoid Eupatilin (HY-N0783), is orally active. Recoflavone can inhibit the NF-κB pathway and induce [Ca( 2+)]i increase in epithelial cells. Recoflavone exhibits activities such as anti-inflammation, anti-tumor effects, protection of gastric and intestinal mucosa, and promotion of secretion in the ocular surface and salivary glands. Recoflavone can be used for the research of diseases such as dry eye, gastric injury, and intestinal injury .
    Recoflavone
  • HY-P1108
    Astressin 2B
    1 Publications Verification

    		 CRFR Neurological Disease Inflammation/Immunology
    Astressin 2B is a blood-brain barrier-impermeable, highly selective CRFR2 antagonist (rCRFR2, IC50=0.57 nM). Astressin 2B blocks the protective effects mediated by CRFR2, thereby exacerbating indomethacin (HY-14397)-induced hemorrhagic intestinal injury in rats. Astressin 2B reverses the protective effects of Urocortin 1 against intestinal hypermotility, bacterial invasion and upregulation of inflammatory mediators. Astressin 2B also blocks the anxiogenic effect of Urocortin 2 and attenuates stress-induced anxiety-related behaviors. In the Clostridioides difficile toxin A (C. difficile toxin A)-mediated enteritis model, Astressin 2B mimics the phenotype of CRFR2-deficient mice, significantly exacerbating intestinal epithelial damage, edema, neutrophil migration and the expression of multiple proinflammatory cytokines. Astressin 2B is an important tool molecule for investigating the intestinal protective mechanisms of CRFR2 .
    Astressin 2B
  • HY-N15135
    Arabinoxylan (Medium viscosity)

    		Interleukin Related Toll-like Receptor (TLR) Fungal Metabolic Disease
    Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .
    Arabinoxylan (Medium viscosity)
  • HY-126848
    Diclofenac acyl glucuronide

    D-1-O-G

    		 Drug Metabolite SOD COX Reactive Oxygen Species (ROS) OAT Inflammation/Immunology
    Diclofenac acyl glucuronide (D-1-O-G) is an orally active glucuronide metabolite of Diclofenac (HY-15036). Diclofenac acyl glucuronide exhibits SOD inhibitory activity, COX-1 inhibitory activity (IC50 = 0.620 μM), and COX-2 inhibitory activity (IC50 = 2.91 μM). Diclofenac acyl glucuronide induces reactive oxygen species (ROS) production and acts as a substrate of OATP2B1. Diclofenac acyl glucuronide induces small intestinal ulcers . Diclofenac acyl glucuronide can be used in research related to intestinal diseases and small intestinal ulcers .
    Diclofenac acyl glucuronide
  • HY-W040088
    L-Alanyl-L-leucine

    H-Ala-Leu-OH

    		 Aminopeptidase Metabolic Disease
    L-Alanyl-L-leucine is a competitive inhibitor of small intestinal glycyl-L-leucine hydrolase with Ki values of 0.53 mM (phosphate buffer) or 0.22 mM (Tris buffer). L-Alanyl-L-leucine can be used for research on Hartnup disease and cystinuria .
    L-Alanyl-L-leucine
  • HY-P2221B
    Glepaglutide acetate
    1 Publications Verification

    ZP1848 acetate

    		 GCGR Inflammation/Immunology
    Glepaglutide (ZP1848) acetate, a long-acting GLP-2 analogue, is a potent GLP-2R agonist. Glepaglutide acetate reduces faecal output and increases intestinal absorption. Glepaglutide acetate alleviates small intestinal inflammation. Glepaglutide acetate can be used in the research of inflammatory bowel disease (IBD) and Crohn’s disease .
    Glepaglutide acetate
  • HY-B1190A
    Cefadroxil hydrate
    5 Publications Verification

    BL-S 578 hydrate

    		 Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil hydrate
  • HY-B1731
    Phenyl salicylate

    		Bacterial Neurological Disease
    Phenyl salicylate (PS) has antibacterial activity when hydrolyzed in small intestine and is often used as nervous system inhibitor and intestinal preservative .
    Phenyl salicylate
  • HY-P2758
    Diamine oxidase

    DAO

    		 Biochemical Assay Reagents Metabolic Disease Inflammation/Immunology Cancer
    Diamine oxidase (DAO) is an orally active enzyme. Diamine oxidase catalyzes oxidative deamination of various polyamines. Diamine oxidase degrades histamine and polyamines to maintain the metabolic balance of amines in the body. Diamine oxidase is a key regulatory enzyme in rapidly proliferating tissues such as bone marrow and intestinal mucosa. Diamine oxidase can be used in research related to intestinal diseases, small bowel transplant rejection, histamine intolerance, and other conditions .
    Diamine oxidase
  • HY-114299S
    Salcaprozate-d4 sodium

    SNAC-d4 sodium

    		 Isotope-Labeled Compounds Others
    Salcaprozate-d4 (sodium) is a deuterated labeled Salcaprozate (sodium) . Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .
    Salcaprozate-d4 sodium
  • HY-128421
    Tridecanedioic acid

    Brassylic Acid

    		 Endogenous Metabolite Parasite Infection Metabolic Disease
    Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is related to the metabolic regulation of non-alcoholic fatty liver disease (NASH) and may be an important node molecule in the intestinal microbiota-host metabolism interaction network. Tridecanedioic acid is significantly accumulated in tolerant cabbage-type rapeseed varieties and has a lower content in sensitive varieties. It plays an important role in the defense response against the infection of the small cabbage moth (Plutella xylostella). Tridecanedioic acid can be used as a biomarker for plant insect resistance or a diagnostic marker for metabolic diseases .
    Tridecanedioic acid
  • HY-B0113R
    Omeprazole (Standard)

    H 16868 (Standard)

    		 Reference Standards Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (Standard) is the analytical standard of Omeprazole. This product is intended for research and analytical applications. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole (Standard)
  • HY-B0113S
    Omeprazole-d3
    1 Publications Verification

    H 16868-d3

    		 Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole-d3 (H 16868-d3) is deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole-d3
  • HY-121811
    Pongamol

    Lanceolatin C

    		 Glycosidase Phosphatase Interleukin Related TNF Receptor COX Beclin1 GLUT FAK Akt mTOR p38 MAPK Keap1-Nrf2 Apoptosis Amyloid-β Tau Protein Autophagy Neurological Disease Inflammation/Immunology Cancer
    Pongamol is an orally active flavonoid with an IC50 of 75 μM and a Ki of 58 μM against PTPase-1B, and an IC50 of 103.5 μM against intestinal α-Glycosidase. Pongamol reduces the release of IL‑1β, TNF‑α, COX‑2 and iNOS in cells, reverses the nuclear translocation of NF‑κB, and upregulates the levels of Beclin 1 and LC3 Ⅱ/LC3 Ⅰ. Pongamol promotes glucose uptake by increasing the level of GLUT4 on the surface of skeletal muscle cells. Pongamol inhibits epithelial-mesenchymal transition by suppressing the FAK/Akt-mTOR signaling pathway. Pongamol inhibits neuronal cytotoxicity, suppresses cell apoptosis and extends the lifespan of Caenorhabditis elegans by activating the MAPKs/Nrf2 signaling pathway. Pongamol exerts hypoglycemic effects in diabetic mouse models. Pongamol alleviates oxidative stress, neuroinflammation, Aβ deposition and excessive phosphorylation of Tau Protein, and restores autophagy function in Alzheimer's disease mouse models by inhibiting the Akt/mTOR signaling pathway. Pongamol is applicable to research related to Alzheimer's disease, type 2 diabetes, non-small cell lung cancer and postprandial hyperglycemia .
    Pongamol
  • HY-154912
    PAT1inh-B01

    		Chloride Channel Inflammation/Immunology
    PAT1inh-B01 is a selective SLC26A6 inhibitor. PAT1inh-B01 inhibits PAT1 (a Cl -/HCO3 - exchanger)-mediated anion exchange (IC50: 350 nM). PAT1inh-B01 blocks fluid absorption in small intestine. PAT1inh-B01 can be used for research of small intestinal hyposecretory disorders .
    PAT1inh-B01
  • HY-114299R
    Salcaprozate sodium (Standard)

    SNAC (Standard)

    		 Biochemical Assay Reagents Reference Standards Others
    Salcaprozate (sodium) (Standard) is the analytical standard of Salcaprozate (sodium). This product is intended for research and analytical applications. Salcaprozate sodium (SNAC), an oral absorption promoter, and has the potential as a delivery agent for oral forms of heparin and insulin. Salcaprozate sodium could increase passive transcellular permeation across small intestinal epithelia based on increased lipophilicity arising from non-covalent macromolecule complexation .
    Salcaprozate sodium (Standard)
  • HY-16569B
    Colchicine,suitable for plant cell culture

    		Biochemical Assay Reagents Microtubule/Tubulin Inflammation/Immunology Cancer
    Colchicine,suitable for plant cell culture, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine,suitable for plant cell culture can be used for plant cell culture .
    Colchicine,suitable for plant cell culture
  • HY-119741
    Salacinol

    		Glycosidase Lipase Metabolic Disease
    Salacinol, compound found in Salacia reticulata, is an orally active α-glucosidase/lipase inhibitor. Salacinol inhibits enzymatic activity of intestinal maltase (IC50 = 3.2 μg/mL, Ki = 0.31 μg/mL), sucrase (IC50 = 0.84 μg/mL, Ki = 0.32 μg/mL), and isomaltase (IC50 = 0.59 μg/mL, Ki = 0.47 μg/mL), and inhibits increases in serum glucose levels in sucrose-loaded rats. Salacinol also inhibits pancreatic lipase and lipoprotein lipase. Salacinol can be used for the research of diabetes mellitus .
    Salacinol
  • HY-16569R
    Colchicine (Standard)

    		Reference Standards Microtubule/Tubulin NOD-like Receptor (NLR) Autophagy Apoptosis Cancer
    Colchicine (Standard) is the analytical standard of Colchicine. This product is intended for research and analytical applications. Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research .
    Colchicine (Standard)
  • HY-109546
    Omeprazole magnesium

    		Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole (H 16868) magnesium is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole magnesium competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole magnesium inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole magnesium inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole magnesium alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole magnesium aslo has neuroprotective and antibacterial effects .
    Omeprazole magnesium
  • HY-B0113S3
    Omeprazole-13C,d3

    H 16868-13C,d3

    		 Isotope-Labeled Compounds Na+/K+ ATPase Interleukin Related Proton Pump Cytochrome P450 Bacterial Apoptosis Autophagy TNF Receptor Atg8/LC3 Infection Metabolic Disease Cancer
    Omeprazole- 13C,d3 is a 13C-labeled and deuterium labeled Omeprazole. Omeprazole (H 16868) is an orally active H +,K +-ATPase inhibitor and a proton pump inhibitor. Omeprazole competitively inhibits CYP2C19, CYP3A4, and CYP2C9 activity. Omeprazole inhibits gastric acid secretion and can be used for acid-related gastrointestinal disorders. Omeprazole inhibits pancreatic cancer cell proliferation, induces apoptosis, autophagosome accumulation (elevated LC3-I and LC3-II levels), oxidative stress, and cytogenetic imbalance, modulates lysosomal transport, reduces inflammatory cytokines. Omeprazole alters small intestinal morphology and magnesium absorption, and induces gastric mucosa morphologic changes. Omeprazole aslo has neuroprotective and antibacterial effects .
    Omeprazole-13C,d3
  • HY-135319
    Strictinin

    		Bacterial Antibiotic ERK JNK NF-κB ROR Apoptosis Caspase GSK-3 Akt PI3K Infection Metabolic Disease Inflammation/Immunology Cancer
    Strictinin is an orally active phenolic compound. Strictinin reduces xanthine oxidase activity, uric acid production, and the activation of ERK1/2, JNK, NF-κB, and NLRP3 inflammasome components in hepatocytes treated with Xanthine (HY-W017389). Strictinin decreases elevated serum uric acid levels and enhanced xanthine oxidase activity in mice treated with potassium oxonate. Strictinin acts as a ROR1 inhibitor and exhibits anticancer activity against highly aggressive non-androgen-dependent prostate cancer. Strictinin induces cancer cell apoptosis (apoptosis), arrests cell cycle, and inhibits cancer cell migration, invasion, and epithelial-mesenchymal transition. Strictinin modulates gut microbiota, inhibits bacterial growth and biofilm formation, accelerates small intestinal transit, and blocks viral entry and replication. Strictinin can be used in research related to hyperuricemia, androgen receptor-negative non-androgen-dependent prostate cancer, triple-negative breast cancer, bacterial infections, constipation, coronavirus infections, dental caries, and infections caused by influenza A, influenza B, and human parainfluenza virus type 1 .
    Strictinin
  • HY-154912A
    PAT1inh-B01 hydrochloride

    		Chloride Channel Inflammation/Immunology
    PAT1inh-B01 hydrocholide is a selective SLC26A6 inhibitor. PAT1inh-B01 hydrocholide inhibits PAT1 (a Cl -/HCO3 - exchanger)-mediated anion exchange (IC50: 350 nM). PAT1inh-B01 hydrocholide blocks fluid absorption in small intestine. PAT1inh-B01 hydrocholide can be used for research of small intestinal hyposecretory disorders .
    PAT1inh-B01 hydrochloride
  • HY-W040088R
    L-Alanyl-L-leucine (Standard)

    H-Ala-Leu-OH (Standard)

    		 Reference Standards Aminopeptidase Metabolic Disease
    L-Alanyl-L-leucine is an endogenous metabolite. This product is used for research and analytical applications. L-Alanyl-L-leucine is a competitive inhibitor of small intestinal glycyl-L-leucine hydrolase with Ki values of 0.53 mM (phosphate buffer) or 0.22 mM (Tris buffer). L-Alanyl-L-leucine can be used for research on Hartnup disease and cystinuria .
    L-Alanyl-L-leucine (Standard)
  • HY-W097994
    DHMB

    2,3-Dihydroxy-4-methoxybenzaldehyde

    		 Fungal Infection Inflammation/Immunology
    DHMB (2,3-Dihydroxy-4-methoxybenzaldehyde) is a small organic molecule with anti-fungal and anti-inflammatory activity. DHMB has protective effect on intestinal epithelial cells .
    DHMB
  • HY-B1190R
    Cefadroxil (Standard)

    BL-S 578 (Standard)

    		 Reference Standards Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil (Standard) is the analytical standard of Cefadroxil (HY-B1190). This product is intended for research and analytical applications. Cefadroxil is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil (Standard)
  • HY-106327
    EM-523

    		Motilin Receptor Metabolic Disease
    EM-523 is a motilin agonist and an erythromycin derivative. EM-523 has pED50 values of 8.19 and 6.08 for promoting contractions in rabbit small intestinal tissue and human duodenal tissue, respectively. EM-523 can be used in the research of gastrointestinal diseases .
    EM-523
  • HY-128421R
    Tridecanedioic acid (Standard)

    Brassylic Acid (Standard)

    		 Reference Standards Endogenous Metabolite Parasite Infection Metabolic Disease
    Tridecanedioic acid (Standard) is the analytical standard of Tridecanedioic acid (HY-128421). This product is intended for research and analytical applications. Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is an endogenous metabolite. Tridecanedioic acid is related to the metabolic regulation of non-alcoholic fatty liver disease (NASH) and may be an important node molecule in the intestinal microbiota-host metabolism interaction network. Tridecanedioic acid is significantly accumulated in tolerant cabbage-type rapeseed varieties and has a lower content in sensitive varieties. It plays an important role in the defense response against the infection of the small cabbage moth (Plutella xylostella). Tridecanedioic acid can be used as a biomarker for plant insect resistance or a diagnostic marker for metabolic diseases.
    Tridecanedioic acid (Standard)
  • HY-W153897
    N-Methyltyramine

    		Adrenergic Receptor Metabolic Disease
    N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .
    N-Methyltyramine
  • HY-B1190S
    Cefadroxil-d4 hydrate

    BL-S 578-d4 hydrate

    		 Isotope-Labeled Compounds Bacterial Antibiotic EAAT Infection Neurological Disease
    Cefadroxil-d4 (hydrate) is the deuterium labeled Cefadroxil hydrate (HY-B1190A). Cefadroxil hydrate is an orally active broad-spectrum cephalosporin antibiotic. Cefadroxil hydrate inhibits bacterial cell wall synthesis and enhances the expression of glutamate transporter-1. Cefadroxil hydrate is dependent on the intestinal peptide transporter PepT1 for small intestinal absorption. Cefadroxil hydrate has inhibitory and bactericidal activity against a variety of Gram-positive and Gram-negative bacteria and has analgesic effects on neuropathic pain .
    Cefadroxil-d4 hydrate
  • HY-14495
    BMS-604992

    EX-1314

    		 GHSR Metabolic Disease
    BMS-604992 (EX-1314) is a selective, orally active small-molecule growth hormone secretagogue receptor (GHSR) agonist. BMS-604992 demonstrates high-affinity binding (Ki=2.3 nM) and potent functional activity (EC50=0.4 nM). BMS-604992 can stimulate food intake in rodents .
    BMS-604992
  • HY-177878
    IMU-856

    		Sirtuin Inflammation/Immunology
    IMU-856 is an orally active and systemic action SIRT6 small molecule regulator. IMU-856 effectively and selectively inhibits the deacetylase activity of SIRT6, while increasing the protein level of SIRT6. IMU-856 can restore intestinal barrier function and can be used for research on celiac disease .
    IMU-856
  • HY-129278
    Lunarine

    		Parasite Infection Cardiovascular Disease Neurological Disease
    Lunarine is an alkaloid, which can be isolated from the seeds of kale (Lunaria annua). Lunarine lowers the blood pressure, stimulates small intestinal motility, inhibits spontaneous contractions of uterus and nervous system, and exhibits an acute toxicity with LD50 of 62.3 mg/kg in dogs and rabbits. Lunarine exhibits antiparasitic activity through a competitive inhibition of protozoan oxidoreductase trypanothione reductase (TryR) with Ki of 304 μM .
    Lunarine
  • HY-106981
    Orazipone

    OR 1384

    		 NADPH Oxidase Reactive Oxygen Species (ROS) Apoptosis NF-κB NO Synthase STAT Inflammation/Immunology
    Orazipone (OR 1384) is a small molecule immunomodulator with strong anti-inflammatory properties. Orazipone exerts its immunomodulatory effect by forming reversible thiol complexes, which bind to intracellular signaling proteins and the thiol groups of glutathione. Orazipone exhibits potent anti-eosinophilic activity by inducing apoptosis. Orazipone inhibits activation of inflammatory transcription factors NF-kB and STAT 1 and decreases inducible iNOS expression and NO production in response to inflammatory stimuli. Orazipone reduces NADPH oxidase activity and thereby decreases ROS production. Orazipone has a protective effect in intestinal radiation injury .
    Orazipone
  • HY-W153897R
    N-Methyltyramine (Standard)

    		Adrenergic Receptor Reference Standards Metabolic Disease
    N-Methyltyramine (Standard) is the analytical standard of N-Methyltyramine. This product is intended for research and analytical applications. N-Methyltyramine is a protoalkaloid that can be isolated from various plant species. N-Methyltyramine is an α2-adrenoreceptor antagonist. N-Methyltyramine enhances appetite and digestion of foods by stimulating gastrin and pancreatic secretions. N-Methyltyramine can relax mouse small intestinal smooth muscle and inhibits small intestinal propulsion .
    N-Methyltyramine (Standard)
  • HY-P1142
    GLP-2(rat)

    		Apoptosis Others
    GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .
    GLP-2(rat)
  • HY-P1142A
    GLP-2(rat) TFA

    		Apoptosis Others
    GLP-2(rat) TFA is an intestinal growth factor. GLP-2(rat) TFA stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) TFA enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR) .
    GLP-2(rat) TFA
  • HY-P1142S
    GLP-2(rat) (Ala-13C3,15N)

    		Isotope-Labeled Compounds Others
    GLP-2(rat) (Ala- 13C3, 15N) is 13C and 15N labeled GLP-2(rat) (HY-P1142). GLP-2(rat) is an intestinal growth factor. GLP-2(rat) stimulates cell proliferation and inhibits apoptosis. GLP-2(rat) enhances mucosal mass and function in residual small intestine after massive small bowel resection (MSBR).
    GLP-2(rat) (Ala-13C3,15N)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: